Gilead Sciences stock rises 2.11% and outperforms competitors

13 articles · Updated · MarketWatch · May 6

The shares closed at $136.30 on Wednesday, extending gains to a fifth straight session as the S&P 500 rose 1.46% and the Dow added 1.24%.
Gilead outpaced peers including Johnson & Johnson, down 0.41%, Pfizer, up 0.30%, and Abbott Laboratories, down 1.00%.
The stock remains 13.34% below its 52-week high of $157.29 reached on 11 February, while trading volume of 6.1 million matched its 50-day average.

Gilead just spent $14.5B on its future, so why is its CEO selling millions in stock?

Can Gilead's multi-billion dollar cancer drug acquisitions outpace its declining COVID-19 revenue?

Will Gilead's expensive new therapies survive the government's aggressive drug price negotiations?